HIV in 2026

HIV in 2026 is not the same epidemic it was in 2016, or 1996, or 1986. The medical reality has been transformed by science. But the epidemic itself — the people still being diagnosed, the communities still bearing disproportionate burdens, the structural barriers that keep prevention and treatment out of reach — is very much ongoing. This is where things stand.

The U.S. epidemic in numbers

These numbers tell a story of both progress and persistent failure. New infections have declined significantly from the peak — from an estimated 130,400 in 1984 and 1985 to roughly 31,800 today, a 73% drop over four decades.^[5] But 31,800 new infections a year is still a crisis. The tools to prevent virtually all of those infections exist. The gap between what's possible and what's happening is political, structural, and economic — not scientific.

The roughly one-third of people with diagnosed HIV who have not reached viral suppression represent the most urgent challenge in domestic HIV.^[4] They include people who know their status but aren't in care, people in care but not on treatment, and people on treatment but not yet suppressed. Each gap in the cascade has specific drivers — and specific solutions.

Treatment in 2026

The standard of care

Modern first-line HIV treatment is a single pill taken once daily — typically a complete regimen in one tablet combining an integrase strand transfer inhibitor (INSTI) with two other agents. The federal HHS treatment guidelines list bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) and dolutegravir-based combinations among the recommended initial regimens for most people with HIV.^[6] These regimens are highly effective, generally well tolerated, and have a high genetic barrier to resistance.

Most people starting modern ART reach an undetectable viral load within a few weeks to a few months. With early diagnosis and consistent treatment, life expectancy for a person with HIV can now approach that of the general population.^[7] This is the reality of HIV treatment in 2026.

Long-acting treatment — a fundamental shift

Long-acting injectable ART has moved from clinical trials to standard practice over the past several years, and it represents a fundamental shift in what HIV treatment can look like.

Cabenuva (cabotegravir + rilpivirine) — given by injection every one or two months — became the first complete long-acting ART regimen when the FDA approved it in January 2021.^[8] For people who are virally suppressed on oral ART and want to eliminate the daily pill, it offers equivalent efficacy with a very different day-to-day experience.

Sunlenca (lenacapavir) — a twice-yearly subcutaneous injection — was first approved by the FDA in December 2022 for heavily treatment-experienced adults with multi-drug-resistant HIV, and is now being studied for broader use.^[9] Six months between injections represents the furthest end of the long-acting spectrum currently available for treatment.

Long-acting treatment is particularly promising for people who struggle with daily pill adherence — whether due to privacy concerns, housing instability, substance use, or simply the psychological burden of a daily reminder of HIV. The treatment landscape of 2026 offers options that would have seemed like science fiction twenty years ago.

Prevention in 2026

The prevention toolkit has never been more powerful

In 2026, HIV prevention has more tools available than at any point in the epidemic's history — and the gap between what's available and what's being used remains enormous.

Oral PrEP (Truvada, Descovy) — reduces the risk of getting HIV from sex by about 99% when taken as prescribed.^[10] FDA-approved since 2012.^[11] Still dramatically underused, particularly among Black and Latino communities and women who could benefit most.

Injectable PrEP (Apretude/cabotegravir every 2 months) — approved by the FDA in December 2021 as the first long-acting PrEP option and shown superior to daily oral PrEP in the HPTN 083 and HPTN 084 trials.^[12] Removes the daily pill burden and the privacy risk of a visible daily medication.

Yeztugo (lenacapavir) for PrEP — on June 18, 2025, the FDA approved Yeztugo, a twice-yearly subcutaneous injection, as the first and only twice-yearly PrEP option in the United States.^[13] Approval was based on the PURPOSE 1 trial, which showed zero HIV infections among 2,134 cisgender women in sub-Saharan Africa given Yeztugo, and PURPOSE 2, in which 99.9% of participants across a broader population — including cisgender men, transgender men and women, and gender-nonbinary people who have sex with men — remained HIV-negative.^[14] Two shots a year, near-total protection.

U=U — Undetectable = Untransmittable — means that people with HIV who reach and maintain an undetectable viral load on treatment have effectively no risk of sexually transmitting HIV to a partner, a consensus endorsed by CDC and hundreds of health organizations worldwide.^[15] Combined with widespread PrEP access, the mathematical potential to bring new infections to near zero exists. Achieving it requires addressing the access, awareness, and structural barriers that keep these tools out of reach for the people who need them most.

Cure research: where it actually stands

HIV cure research has produced several striking results in recent years — while also clarifying the extraordinary scientific difficulty of eliminating a virus that integrates into the genome and establishes latent reservoirs that current drugs suppress but cannot reach.

Documented cures

A small number of individuals have achieved apparent HIV cures after allogeneic stem cell transplants for blood cancers, most from donors with the rare CCR5-delta32 mutation that produces immune cells resistant to HIV.^[16] The Berlin Patient (Timothy Ray Brown), the London Patient (Adam Castillejo), the Düsseldorf Patient, the City of Hope Patient (Paul Edmonds), and a small number of others have been described as functionally cured through this approach; a seventh case, involving a donor with just one copy of the CCR5-delta32 mutation, was reported at AIDS 2024. But stem cell transplantation is a high-risk procedure indicated only for life-threatening blood cancers — it is not a scalable treatment path for the general HIV population.

Broadly neutralizing antibodies (bNAbs)

Broadly neutralizing antibodies — engineered antibodies that can recognize and neutralize HIV across multiple strains — are one of the most promising active research areas. Some bNAb combinations have produced long-term viral suppression after stopping standard ART in subsets of trial participants. Clinical trials are ongoing. bNAbs represent a potential path to functional remission or cure for people who respond to them, though not everyone does and the response varies by viral characteristics.

"Kick and kill" and reservoir strategies

HIV hides in latent reservoirs — primarily resting CD4 T cells — where it is invisible to the immune system and current drugs. "Kick and kill" (or "shock and kill") strategies aim to reactivate these latent reservoirs so that the immune system can eliminate them. Results have been mixed; fully clearing the reservoir has proven more difficult than early research suggested. This remains an active area but is further from clinical application than bNAbs.

Gene editing

CRISPR-based approaches to excising HIV from the genome are in early clinical development. Proof-of-concept results have been promising in animal models and initial human safety trials. This remains early-stage science, but the direction is real and the investment is significant.

The honest assessment of cure research in 2026: meaningful progress, real momentum, but no cure available outside of specific stem cell transplant contexts. Functional remission for some people — the ability to maintain viral suppression after stopping ART — may be closer than full cure. Lifelong ART remains the standard for the vast majority of PLHIV in 2026.

Ending the HIV Epidemic

The Ending the HIV Epidemic in the U.S. (EHE) initiative, launched in 2019, set a goal of cutting new HIV infections in the United States by 75% by 2025 and 90% by 2030.^[17] The strategy focused federal resources on 57 priority jurisdictions — 48 counties, Washington, D.C., Puerto Rico, and 7 states with a high rural HIV burden — that together account for more than half of new U.S. HIV diagnoses.

Progress through 2024 was real but insufficient to meet the 2030 target. New infections declined 12% from 2018 to 2022, driven largely by a 30% drop among people aged 13–24, but the overall pace fell well short of the 75%-by-2025 milestone.^[18] The disparities that drive the epidemic — in Black and Latino communities, in the South, and in people who inject drugs — proved resistant to programmatic interventions alone, because they are rooted in structural inequities that HIV programs cannot address unilaterally.

Funding threats and the political environment

The HIV epidemic does not exist in a political vacuum. In 2025 and 2026, the HIV response in the United States faces funding and policy threats that have not been seen since the early epidemic:

PEPFAR: The President's Emergency Plan for AIDS Relief — credited by the U.S. State Department with saving more than 25 million lives since 2003 — has faced proposed funding cuts and operational disruptions.^[19] PEPFAR funds HIV treatment for tens of millions of people in sub-Saharan Africa, where the global epidemic is most severe. Cuts would have immediate mortality consequences.

CDC prevention funding: Federal CDC funding for domestic HIV prevention — which supports testing, PrEP programs, and community outreach — has been targeted in budget proposals. Reductions in prevention funding would directly increase new infections.

Ryan White and ADAP: Florida's ADAP program cut eligibility from 400% to 130% of the federal poverty level on March 1, 2026, disenrolling more than 12,000 Floridians (NASTAD initially estimated as many as 16,000 could be affected) before the legislature restored eligibility to 400% FPL later that month through emergency bridge funding.^[20] Federal Ryan White funding uncertainty adds further instability. Full context is in the Florida section below and on our ADAP Updates page.

The human rights environment: As of 2025, 32 states still had HIV-specific criminalization laws on the books, and 28 states had criminal penalty enhancements tied to a person's knowledge of their HIV status.^[21] The legal environment for LGBTQ+ communities — who bear disproportionate HIV burden — has become more hostile in several states. Immigration enforcement creates fear that reduces HIV testing and care-seeking among undocumented communities.

The science of HIV in 2026 is remarkable. The tools exist to get to near-zero new infections. What stands between where we are and that goal is not biology — it is political will, structural investment, and the removal of the barriers that keep the most affected communities from the tools that could protect them.

Florida in 2026

Florida remains one of the highest-burden states for HIV in the nation, and 2026 has been a turbulent year for HIV care access in the state.^[22] The Florida ADAP eligibility cut — announced in January, implemented March 1, and reversed by the legislature later that month — was the most significant HIV care disruption Florida has seen in over a decade, and its resolution shows both how fragile and how resilient the state's HIV safety net is.

Beyond ADAP, Florida has one of the most aggressive HIV criminalization statutes in the country, and it has not been updated to reflect modern science.^[21] HIV stigma in Florida — particularly in rural areas and in communities of color — remains a significant barrier to testing and care. Florida's decision not to expand Medicaid under the Affordable Care Act also leaves a coverage gap that affects tens of thousands of Floridians living with HIV.

The Florida HIV care infrastructure — Ryan White clinics, AIDS service organizations, FQHC networks, CAN Community Health, AHF — is robust and committed. The gap is between what that infrastructure can do and the structural and political barriers it has to work around.

RiseUpToHIV was built specifically in response to Florida's HIV crisis — to fill information gaps, connect people to care, and refuse to let the epidemic proceed invisibly. That mission is more relevant in 2026 than when we started.

References & Sources

1. HIV.gov. U.S. Statistics. At year-end 2022, an estimated 1.2 million people ages 13 and older in the U.S. had HIV (diagnosed and undiagnosed). hiv.gov. ↩
2. CDC. New HIV Surveillance Reports: Estimated HIV Incidence and Prevalence in the United States, 2018–2022. An estimated 31,800 people acquired HIV in the U.S. in 2022, a 12% decline from 2018. cdc.gov. ↩
3. HIV.gov. U.S. Statistics. About 13% (roughly 158,249) of people living with HIV in the U.S. don't know they have it. hiv.gov. ↩
4. CDC. National HIV Prevention and Care Objectives: 2026 Update. Among more than 1.1 million people with diagnosed HIV at year-end 2024, 69% had achieved viral suppression in 2024. cdc.gov. ↩ ↩
5. CDC MMWR. Estimated Annual Number of HIV Infections — United States, 1981–2019. MMWR 2021;70(22):801–806. Estimated annual HIV incidence rose from 20,000 in 1981 to a peak of 130,400 in 1984 and 1985, then declined to 34,800 in 2019. cdc.gov. ↩
6. National Institutes of Health, ClinicalInfo.HIV.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV: What to Start. Recommended initial regimens for most people with HIV include bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) and dolutegravir-based combinations. clinicalinfo.hiv.gov. ↩
7. HIV.gov. Living Well with HIV. People diagnosed with HIV who start treatment early and stay on it can achieve a life expectancy close to that of the general population. hiv.gov. ↩
8. FDA. Drug Trials Snapshot: CABENUVA (cabotegravir and rilpivirine). Approved January 21, 2021 as the first complete long-acting HIV treatment regimen for adults with virologic suppression. fda.gov. ↩
9. FDA. FDA Approves New HIV Drug for Adults with Limited Treatment Options (December 22, 2022). Sunlenca (lenacapavir) approved for heavily treatment-experienced adults with multi-drug-resistant HIV. fda.gov. ↩
10. CDC. PrEP Effectiveness. When taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99%. cdc.gov. ↩
11. FDA. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection (July 16, 2012). Approval of Truvada (emtricitabine/tenofovir disoproxil fumarate) as PrEP. fda.gov. ↩
12. FDA. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention (December 20, 2021). Apretude (cabotegravir extended-release injectable suspension) approved as the first long-acting injectable PrEP option. fda.gov. ↩
13. Gilead Sciences. Yeztugo (Lenacapavir) Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection (press release, June 18, 2025). gilead.com. ↩
14. Bekker LG, Das M, Abdool Karim Q, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024;391(13):1179–1192 (PURPOSE 1); and Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2024 (PURPOSE 2). nejm.org. ↩
15. Prevention Access Campaign. U=U (Undetectable = Untransmittable). Consensus statement, endorsed by CDC and hundreds of health organizations worldwide, that people with sustained undetectable HIV have effectively no risk of sexually transmitting the virus. preventionaccess.org. ↩
16. European AIDS Treatment Group. The next Berlin Patient: Another man cured of HIV after stem cell transplant (AIDS 2024 conference coverage). Review of documented HIV cures via allogeneic stem cell transplants and the CCR5-delta32 mutation. eatg.org. ↩
17. HIV.gov. Ending the HIV Epidemic in the U.S.: Overview. EHE aims to reduce new HIV infections in the U.S. by 75% by 2025 and 90% by 2030, focused on 57 priority jurisdictions. hiv.gov. ↩
18. HIV.gov. U.S. Statistics. New HIV infections decreased 12% from 36,200 in 2018 to 31,800 in 2022, driven by a 30% decrease among people aged 13–24. hiv.gov. ↩
19. U.S. Department of State, Office of the U.S. Global AIDS Coordinator. PEPFAR: Latest Global Results. The State Department credits PEPFAR with saving more than 25 million lives since 2003. state.gov. ↩
20. Miami Herald. DeSantis signs bill to extend affordable AIDS drugs program through end of June (March 24, 2026). Legislative rescue of Florida ADAP after March 1 eligibility cuts affected approximately 12,000 Floridians. miamiherald.com. ↩
21. Center for HIV Law and Policy. Mapping HIV Criminalization Laws in the U.S. (2025). 32 states have HIV-specific exposure or transmission laws; 28 states have criminal penalty enhancements tied to HIV status. hivlawandpolicy.org. ↩ ↩
22. CDC. Diagnoses, Deaths, and Prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2023. Florida remains among the highest-burden states for HIV; the South accounted for roughly half of new HIV infections in 2022. stacks.cdc.gov. ↩
23. International Association of Providers of AIDS Care (IAPAC). News Alert — Florida ADAP Changes (January 12, 2026). Florida DOH announcement of the March 1 ADAP eligibility change from 400% to 130% FPL. iapac.org. ↩
24. WLRN Public Media. State sued over access to HIV/AIDS medication for low-income Floridians (January 28, 2026). AHF lawsuit and NASTAD estimate that up to 16,000 Floridians would lose ADAP coverage. wlrn.org. ↩
25. Florida Senate. Senate Introduces Bridge Funding for AIDS Medication (March 10, 2026) — and Miami Herald, DeSantis signs bill to extend affordable AIDS drugs program through end of June (March 24, 2026). HB 697 restored 400% FPL eligibility and appropriated $30.9 million through June 30, 2026. flsenate.gov. ↩
26. Florida State Legislature (FY 2026–27 appropriations); coverage summarized by Brief Glance — Florida Reverses HIV Drug Cuts, But Gaps in the Safety Net Remain (June 29, 2026). New budget locks in additional funding for ADAP and restores 400% FPL eligibility with a 21,000-person direct-dispense cap. briefglance.com. ↩